1677 related articles for article (PubMed ID: 25145475)
1. The role of liver fat and insulin resistance as determinants of plasma aminotransferase elevation in nonalcoholic fatty liver disease.
Maximos M; Bril F; Portillo Sanchez P; Lomonaco R; Orsak B; Biernacki D; Suman A; Weber M; Cusi K
Hepatology; 2015 Jan; 61(1):153-60. PubMed ID: 25145475
[TBL] [Abstract][Full Text] [Related]
2. Hepatic Steatosis and Insulin Resistance, But Not Steatohepatitis, Promote Atherogenic Dyslipidemia in NAFLD.
Bril F; Sninsky JJ; Baca AM; Superko HR; Portillo Sanchez P; Biernacki D; Maximos M; Lomonaco R; Orsak B; Suman A; Weber MH; McPhaul MJ; Cusi K
J Clin Endocrinol Metab; 2016 Feb; 101(2):644-52. PubMed ID: 26672634
[TBL] [Abstract][Full Text] [Related]
3. Risk of severe liver disease in nonalcoholic fatty liver disease with normal aminotransferase levels: a role for insulin resistance and diabetes.
Fracanzani AL; Valenti L; Bugianesi E; Andreoletti M; Colli A; Vanni E; Bertelli C; Fatta E; Bignamini D; Marchesini G; Fargion S
Hepatology; 2008 Sep; 48(3):792-8. PubMed ID: 18752331
[TBL] [Abstract][Full Text] [Related]
4. High Prevalence of Nonalcoholic Fatty Liver Disease in Patients With Type 2 Diabetes Mellitus and Normal Plasma Aminotransferase Levels.
Portillo-Sanchez P; Bril F; Maximos M; Lomonaco R; Biernacki D; Orsak B; Subbarayan S; Webb A; Hecht J; Cusi K
J Clin Endocrinol Metab; 2015 Jun; 100(6):2231-8. PubMed ID: 25885947
[TBL] [Abstract][Full Text] [Related]
5. Nonalcoholic steatohepatitis associated with metabolic syndrome: relationship to insulin resistance and liver histology.
Jung KY; Cho SY; Kim HJ; Kim SB; Song IH
J Clin Gastroenterol; 2014; 48(10):883-8. PubMed ID: 24440936
[TBL] [Abstract][Full Text] [Related]
6. Plasma Fibroblast Growth Factor 21 Is Associated With Severity of Nonalcoholic Steatohepatitis in Patients With Obesity and Type 2 Diabetes.
Barb D; Bril F; Kalavalapalli S; Cusi K
J Clin Endocrinol Metab; 2019 Aug; 104(8):3327-3336. PubMed ID: 30848827
[TBL] [Abstract][Full Text] [Related]
7. IMPACT OF TYPE 2 DIABETES ON NONALCOHOLIC STEATOHEPATITIS AND ADVANCED FIBROSIS IN PATIENTS WITH NONALCOHOLIC FATTY LIVER DISEASE.
Bian H; Zhu X; Xia M; Yan H; Chang X; Hu X; Pan B; Guo W; Li X; Gao X
Endocr Pract; 2020 Apr; 26(4):444-453. PubMed ID: 31968197
[No Abstract] [Full Text] [Related]
8. [Clinical and histological features of non-alcoholic fatty liver disease].
Shi JP; Xun YH; Hu CB; Zhang L; Liu H; Lou GQ; Fan JG
Zhonghua Gan Zang Bing Za Zhi; 2009 Nov; 17(11):812-6. PubMed ID: 19958638
[TBL] [Abstract][Full Text] [Related]
9. Combination of Aspartate Aminotranferase and Tumor Necrosis Factor-α as Non Invasive Diagnostic Tools for Non Alcoholic Steatohepatitis (NASH).
Purnomo HD; Mundhofir FE; Kasno ; Sudijanto E; Darmono ; Daldiyono ; Djokomoeljanto R; Faradz SM
Acta Med Indones; 2015 Jan; 47(1):16-23. PubMed ID: 25948763
[TBL] [Abstract][Full Text] [Related]
10. Acetyl-L-carnitine and lipoic acid improve mitochondrial abnormalities and serum levels of liver enzymes in a mouse model of nonalcoholic fatty liver disease.
Kathirvel E; Morgan K; French SW; Morgan TR
Nutr Res; 2013 Nov; 33(11):932-41. PubMed ID: 24176233
[TBL] [Abstract][Full Text] [Related]
11. Predictors of nonalcoholic steatohepatitis in patients with elevated alanine aminotransferase activity.
Puljiz Z; Stimac D; Kovac D; Puljiz M; Bratanić A; Kovacić V; Kardum D; Bonacin D; Hozo I
Coll Antropol; 2010 Mar; 34 Suppl 1():33-7. PubMed ID: 20402293
[TBL] [Abstract][Full Text] [Related]
12. Nonalcoholic steatohepatitis versus steatosis: adipose tissue insulin resistance and dysfunctional response to fat ingestion predict liver injury and altered glucose and lipoprotein metabolism.
Musso G; Cassader M; De Michieli F; Rosina F; Orlandi F; Gambino R
Hepatology; 2012 Sep; 56(3):933-42. PubMed ID: 22684858
[TBL] [Abstract][Full Text] [Related]
13. Alanine aminotransferase levels and fatty liver in childhood obesity: associations with insulin resistance, adiponectin, and visceral fat.
Burgert TS; Taksali SE; Dziura J; Goodman TR; Yeckel CW; Papademetris X; Constable RT; Weiss R; Tamborlane WV; Savoye M; Seyal AA; Caprio S
J Clin Endocrinol Metab; 2006 Nov; 91(11):4287-94. PubMed ID: 16912127
[TBL] [Abstract][Full Text] [Related]
14. Hypoadiponectinemia plays a crucial role in the development of nonalcoholic fatty liver disease in patients with type 2 diabetes mellitus independent of visceral adipose tissue.
Yoneda M; Iwasaki T; Fujita K; Kirikoshi H; Inamori M; Nozaki Y; Maeyama S; Wada K; Saito S; Terauchi Y; Nakajima A
Alcohol Clin Exp Res; 2007 Jan; 31(1 Suppl):S15-21. PubMed ID: 17331160
[TBL] [Abstract][Full Text] [Related]
15. Prevalence and associated metabolic factors of fatty liver disease in the elderly.
Wang Z; Xu M; Peng J; Jiang L; Hu Z; Wang H; Zhou S; Zhou R; Hultström M; Lai EY
Exp Gerontol; 2013 Aug; 48(8):705-9. PubMed ID: 23721951
[TBL] [Abstract][Full Text] [Related]
16. Efficacy of rifaximin on circulating endotoxins and cytokines in patients with nonalcoholic fatty liver disease.
Gangarapu V; Ince AT; Baysal B; Kayar Y; Kılıç U; Gök Ö; Uysal Ö; Şenturk H
Eur J Gastroenterol Hepatol; 2015 Jul; 27(7):840-5. PubMed ID: 26043290
[TBL] [Abstract][Full Text] [Related]
17. Predictive value of ALT levels for non-alcoholic steatohepatitis (NASH) and advanced fibrosis in non-alcoholic fatty liver disease (NAFLD).
Verma S; Jensen D; Hart J; Mohanty SR
Liver Int; 2013 Oct; 33(9):1398-405. PubMed ID: 23763360
[TBL] [Abstract][Full Text] [Related]
18. Risk factors associated with nonalcoholic fatty liver disease and its relationship with the hepatic histological changes.
Rodríguez-Hernández H; Gonzalez JL; Márquez-Ramirez MD; Flores-Hernandez M; Rodríguez-Morán M; Guerrero-Romero F
Eur J Gastroenterol Hepatol; 2008 May; 20(5):399-403. PubMed ID: 18403941
[TBL] [Abstract][Full Text] [Related]
19. Diagnostic accuracy of serum alanine aminotransferase as biomarker for nonalcoholic fatty liver disease and insulin resistance in healthy subjects, using 3T MR spectroscopy.
Martin-Rodriguez JL; Gonzalez-Cantero J; Gonzalez-Cantero A; Arrebola JP; Gonzalez-Calvin JL
Medicine (Baltimore); 2017 Apr; 96(17):e6770. PubMed ID: 28445310
[TBL] [Abstract][Full Text] [Related]
20. Cinnamon may have therapeutic benefits on lipid profile, liver enzymes, insulin resistance, and high-sensitivity C-reactive protein in nonalcoholic fatty liver disease patients.
Askari F; Rashidkhani B; Hekmatdoost A
Nutr Res; 2014 Feb; 34(2):143-8. PubMed ID: 24461315
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
